Journal ArticleDOI
Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.
TLDR
The current technology used for commercial production of recombinant therapeutics in E. coli is summarized and recent advances that can potentially expand the use of this system toward more sophisticated protein therapeutics are summarized.Abstract:
Nearly 30% of currently approved recombinant therapeutic proteins are produced in Escherichia coli. Due to its well-characterized genetics, rapid growth and high-yield production, E. coli has been a preferred choice and a workhorse for expression of non-glycosylated proteins in the biotech industry. There is a wealth of knowledge and comprehensive tools for E. coli systems, such as expression vectors, production strains, protein folding and fermentation technologies, that are well tailored for industrial applications. Advancement of the systems continues to meet the current industry needs, which are best illustrated by the recent drug approval of E. coli produced antibody fragments and Fc-fusion proteins by the FDA. Even more, recent progress in expression of complex proteins such as full-length aglycosylated antibodies, novel strain engineering, bacterial N-glycosylation and cell-free systems further suggests that complex proteins and humanized glycoproteins may be produced in E. coli in large quantities. This review summarizes the current technology used for commercial production of recombinant therapeutics in E. coli and recent advances that can potentially expand the use of this system toward more sophisticated protein therapeutics.read more
Citations
More filters
Journal ArticleDOI
Quorum sensing inhibitors: an overview.
TL;DR: This review focuses primarily on natural and synthetic quorum sensing inhibitors (QSIs) with the potential for treating bacterial infections and it has been opined that the most versatile prokaryotes to produce QSI are likely to be those, which are generally regarded as safe.
Journal ArticleDOI
The unexhausted potential of E. coli
TL;DR: Findings have shed light on aspects of its biology and ecology that pose far-reaching questions and illustrate how an appreciation of E. coli's natural history can expand its value as a model organism.
Journal ArticleDOI
Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development.
TL;DR: Recently, advances have been made in the various areas of bioprocessing and are being utilized to develop effective processes for producing recombinant proteins that can be used as therapeutics, vaccines, and diagnostic reagents.
Journal ArticleDOI
Microbials for the production of monoclonal antibodies and antibody fragments
TL;DR: Glycosylated full length antibodies are currently produced in mammalian cells but can be produced in microbial organisms and microbials provide several advantages over mammalian cells.
Journal ArticleDOI
Cell factories for insulin production.
Nabih A. Baeshen,Mohammed N. Baeshen,Abdullah Sheikh,Roop Singh Bora,Mohamed M. Ahmed,Hassan A. I. Ramadan,Kulvinder Singh Saini,Elrashdy M. Redwan +7 more
TL;DR: This review would focus in this review, on various approaches that can be exploited to increase the production of a biologically active insulin and its analogues in E. coli and yeast.
References
More filters
Journal ArticleDOI
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes
F W Studier,B A Moffatt +1 more
TL;DR: A gene expression system based on bacteriophage T7 RNA polymerase has been developed and high levels of accumulation suggest that the RNAs are relatively stable, perhaps in part because their great length and/or stem-and-loop structures at their 3' ends help to protect them against exonucleolytic degradation.
Journal ArticleDOI
Recombinant protein expression in Escherichia coli.
TL;DR: Recent progress in the fundamental understanding of transcription, translation, and protein folding in E. coli, together with serendipitous discoveries and the availability of improved genetic tools are making this bacterium more valuable than ever for the expression of complex eukaryotic proteins.
Journal ArticleDOI
Automated design of synthetic ribosome binding sites to control protein expression
TL;DR: A predictive method for designing synthetic ribosome binding sites is developed, enabling a rational control over the protein expression level, and is demonstrated by rationally optimizing protein expression to connect a genetic sensor to a synthetic circuit.
Journal ArticleDOI
Codon bias and heterologous protein expression
TL;DR: Redesign strategies are discussed here, including modification of translation initiation regions, alteration of mRNA structural elements and use of different codon biases.
Journal ArticleDOI
Strategies for achieving high-level expression of genes in Escherichia coli.
TL;DR: Progress in the understanding of several biological processes promises to broaden the usefulness of Escherichia coli as a tool for gene expression and the remarkable increase in the availability of fusion partners offers a wide range of tools for improved protein folding, solubility, protection from proteases, yield, and secretion into the culture medium.
Related Papers (5)
Recombinant protein expression in Escherichia coli: advances and challenges.
Production of recombinant proteins by microbes and higher organisms.
Arnold L. Demain,Preeti Vaishnav +1 more